Rocklatan Approved for Glaucoma
March 12, 2019 – The U.S. FDA has approved Rocklatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, manufactured by Aerie Pharmaceuticals, to reduce elevated intraocular pressure (IOP) in patients who have open-angle glaucoma or ocular hypertension. The product is a combination of Rhopressa® (netarsudil ophthalmic solution) 0.02%, also manufactured by Aerie, and latanoprost 0.005%, which is available as both a generic and a brand name medication.
In clinical trials, over 60% of patients treated with Rocklatan experienced an IOP reduction of 30% or more. Side effects were typically mild and tolerable. Almost twice as many patients treated with Rocklatan achieved an IOP of 16 mmHg or lower and nearly three times as many reached an IOP of 14 mmHg or lower compared to latanoprost alone. The recommended dosing with Rocklatan is one drop in the affected eye(s) daily, administered in the evening.